-
EP1812050
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1812050
| EP1812050 - COMPOSITION COMPRISING VLP AND AMYLOID-BETA PEPTIDE [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 22.03.2013 Database last updated on 03.09.2024 | Most recent event Tooltip | 22.03.2013 | Withdrawal of application | published on 24.04.2013 [2013/17] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | [N/P] |
| Former [2009/43] | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | |||
| Former [2007/31] | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
NOVARTIS-PHARMA GMBH Brunner Strasse 59 1230 Vienna / AT | Inventor(s) | 01 /
GRAF, Ana Schaeferstrasse 12A CH-4125 Riehen / CH | 02 /
STAUFENBIEL, Matthias Müllerweg 7 79541 Lörrach / DE | 03 /
BLÄTTLER, Thomas Hof Wisler 5 CH-4461 Böckten / CH | 04 /
PAGANETTI, Paolo Schöllenenstrasse 27 ch-4054 Basel / CH | [2007/31] | Representative(s) | Vögeli-Lange, Regina, et al Novartis AG Corporate Intellectual Property 4002 Basel / CH | [N/P] |
| Former [2007/31] | Vögeli-Lange, Regina, et al Novartis AG Corporate Intellectual Property Basel, 4002 / CH | Application number, filing date | 05801760.9 | 03.11.2005 | [2007/31] | WO2005EP11788 | Priority number, date | GB20040024563 | 05.11.2004 Original published format: GB 0424563 | [2007/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2006048295 | Date: | 11.05.2006 | Language: | EN | [2006/19] | Type: | A1 Application with search report | No.: | EP1812050 | Date: | 01.08.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.05.2006 takes the place of the publication of the European patent application. | [2007/31] | Search report(s) | International search report - published on: | EP | 11.05.2006 | Classification | IPC: | A61K39/00, A61K39/385, A61P25/28, A61P25/00, C07K16/00, A61K47/48 | [2007/31] | CPC: |
A61K9/0019 (EP,US);
A61K39/385 (KR,US);
A61K38/162 (EP,US);
A61K38/22 (EP,US);
A61K39/0007 (EP,US);
A61K45/06 (US);
A61K47/50 (KR);
A61K47/6901 (EP,US);
A61P25/00 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
C07K16/00 (KR);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/31] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | 05.06.2007 | MK | Not yet paid | YU | Not yet paid | Title | German: | ZUSAMMENSETZUNG MIT VLP UND AMYLOID-BETAPEPTID | [2007/31] | English: | COMPOSITION COMPRISING VLP AND AMYLOID-BETA PEPTIDE | [2007/31] | French: | COMPOSITION CONTENANT UNE VLP ET UN PEPTIDE AMYLOIDE BETA | [2007/31] | Entry into regional phase | 05.06.2007 | National basic fee paid | 05.06.2007 | Designation fee(s) paid | 05.06.2007 | Examination fee paid | Examination procedure | 05.06.2007 | Examination requested [2007/31] | 04.06.2008 | Despatch of a communication from the examining division (Time limit: M06) | 20.01.2009 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 20.03.2009 | Reply to a communication from the examining division | 22.10.2010 | Despatch of a communication from the examining division (Time limit: M06) | 12.04.2011 | Reply to a communication from the examining division | 19.03.2013 | Application withdrawn by applicant [2013/17] | 20.03.2013 | Cancellation of oral proceeding that was planned for 07.05.2013 | 07.05.2013 | Date of oral proceedings (cancelled) | Divisional application(s) | EP10175387.9 Application withdrawn : 16.09.2010 | EP10177232.5 / EP2286830 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 04.06.2008 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 20.03.2009 | Request for further processing filed | 20.03.2009 | Full payment received (date of receipt of payment) | Fees paid | Renewal fee | 15.11.2007 | Renewal fee patent year 03 | 31.03.2008 | Renewal fee patent year 04 | 12.11.2009 | Renewal fee patent year 05 | 12.11.2010 | Renewal fee patent year 06 | 14.11.2011 | Renewal fee patent year 07 | 13.11.2012 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [DX]WO02056907 (CYTOS BIOTECHNOLOGY AG [CH], et al) [DX] 1-8 * the whole document *; | [XDY]WO2004016282 (CYTOS BIOTECHNOLOGY AG [CH], et al) [XD] 1-10 * the whole document * [Y] 11-13; | [X] - GEYLIS V ET AL, "P4-388 Human monoclonal antibodies against amyloid-beta (Abeta) engendered by EBV-immortalized lymphocytes from healthy adults", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, (200407), vol. 25, ISSN 0197-4580, page S585, XP004626560 [X] 14-21 * the whole document * DOI: http://dx.doi.org/10.1016/S0197-4580(04)81946-8 | [X] - GASKIN F ET AL, "HUMAN ANTIBODIES REACTIVE WITH BETA-AMYLOID PROTEIN IN ALZHEIMER'S DISEASE", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, (19930401), vol. 177, no. 4, ISSN 0022-1007, pages 1181 - 1186, XP001030627 [X] 14-21 * abstract * DOI: http://dx.doi.org/10.1084/jem.177.4.1181 | [X] - XU S ET AL, "INCREASED INCIDENCE OF ANTI-BETA-AMYLOID AUTOANTIBODIES SECRETED BYEPSTEIN-BARR VIRUS TRANSFORMED B CELL LINES FROM PATIENTS WITH ALZHEIMER'S DISEASE", MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE,, CH, (1997), vol. 94, no. 1 - 3, ISSN 0047-6374, pages 213 - 222, XP001030610 [X] 14-21 * abstract * DOI: http://dx.doi.org/10.1016/S0047-6374(96)01861-1 | [Y] - GOLDE TODD E, "Alzheimer disease therapy: Can the amyloid cascade be halted?", JOURNAL OF CLINICAL INVESTIGATION, (200301), vol. 111, no. 1, ISSN 0021-9738, pages 11 - 18, XP002360366 [Y] 11-13 * page 13, column L, paragraph 3 - page 15, column R, paragraph 1 * DOI: http://dx.doi.org/10.1172/JCI200317527 | [XP] - GEYLIS V ET AL, "Human monoclonal antibodies against amyloid-beta from healthy adults", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, (200505), vol. 26, no. 5, ISSN 0197-4580, pages 597 - 606, XP004748495 [XP] 14-21 * the whole document * DOI: http://dx.doi.org/10.1016/j.neurobiolaging.2004.06.008 | [A] - HOCK C ET AL, "Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, (200211), vol. 8, no. 11, ISSN 1078-8956, pages 1270 - 1275, XP002984204 [A] 14-21 * the whole document * DOI: http://dx.doi.org/10.1038/nm783 | [A] - DU YANSHENG ET AL, "Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.", BRAIN, (200309), vol. 126, no. 9, ISSN 0006-8950, pages 1935 - 1939, XP002360367 [A] 14-21 * the whole document * DOI: http://dx.doi.org/10.1093/brain/awg191 | [A] - LI QINGYOU ET AL, "Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice", BMC NEUROSCIENCE, (20040608), vol. 5, no. June 8, ISSN 1471-2202, XP002360368 [A] 1-21 * the whole document * DOI: http://dx.doi.org/10.1186/1471-2202-5-21 |